News
Novavax COVID Vaccine Moves Closer to Full FDA Approval
Under emergency use, vaccines can be removed even after a health emergency is considered to be over. Full approval from the FDA means a product can stay on the market even after a health emergency ends. (The World Health Organization declared an end to the COVID emergency in May 2023.)
The FDA is asking Novavax for a non-mandatory postmarketing commitment to produce additional clinical data for its ...
Novavax NVAX shares rallied 19.5% in the last trading session to close at $7.47. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session ...
Federal regulators have asked Novavax to complete an additional clinical trial on its COVID-19 vaccine after previously ...
Confusion over the FDA delay in granting full approval to Novavax’s Covid-19 vaccine deepened over the weekend, with possible ...
Novavax (NasdaqGS:NVAX) recently announced preliminary results from its SHIELD-Utah study, showcasing the Novavax COVID-19 vaccine's effectiveness and reduced side effects compared to a competitor's ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback